Global Polymer-based Drug Delivery Systems Market Size & Trends Report Segmented by Route of Administration (Oral, Injectable, Transdermal, Topical), Polymer Type (Natural, Synthetic), Drug Type (Small Molecules, Biologics), End User & Regional Forecast to 2031

The polymer-based drug delivery systems market consists of technology, products and materials containing natural and synthetic polymers used for encapsulating, protecting, and delivering therapeutic agents through controlled, sustained, and targeted means. There are multiple ways in which polymer-based drug delivery systems improve drug stability, bioavailability, and therapeutic effectiveness, while reducing dose frequency and side effects. The polymer-based drug delivery system market is comprised of the different types of polymer-based drug formulations used for various types of drug delivery systems, including but not limited to oral, injectable, topical, ophthalmic, and other routes of administration. Key application of these systems includes the diseases like oncology, diabetes, cardiovascular, neurological, infectious, and auto-immune driven by the advances in materials science, biologicals, nanotechnology, and precision medicine.

Growing demand for controlled and targeted drug delivery to propel market demand

The increasing need for precise and controlled drug delivery is one of the main factors driving the polymer-based drug delivery systems market, as healthcare providers look for ways to provide drugs that are more effective while causing minimal adverse effects. Many traditional drug formulations release their active ingredients rapidly. This rapid release creates wide fluctuations in drug concentration and hence patients need to take medications multiple times each day which increases their risk of developing systemic toxicity. Polymer-based drug delivery systems can address many of these concerns by providing a method for delivering drugs that allows for sustained release at the site of action for a long period of time, thus maintaining therapeutic drug concentration over time. Biodegradable polymers, hydrogels, nanoparticles, and microspheres also help protect drug molecules from degradation prior to reaching their intended site of action and improve the bioavailability of the drug, particularly for biologics and poorly soluble drugs.

Additionally, these technologies also reduce the number of times patients receive medications, improve patient adherence to their medication regimen, and improve overall health in chronic diseases such as cancer, diabetes, and heart disease. Therefore, as pharmaceutical companies develop new precision-based therapies and long-action formulations, the demand for new polymer-based carriers will continue to increase, driving greater innovation, commercialization, and adoption of polymer-based drug delivery systems in many therapeutic areas.

To learn more about this report, download the PDF brochure

Rapid growth of biologics and complex therapeutics is fueling the demand for polymer-based drug delivery systems

The growth of biologics and other complex therapies is rapidly driving the polymer-based drug delivery systems market by increasing the need for advanced delivery technology capable of maintaining stability and efficacy of sensitive drug molecules. Biologics are not like traditional small-molecule drugs as they are more susceptible to enzymatic degradation, have lower bioavailability, and they have a limited circulation time. The use of polymeric carriers makes it possible to protect biologics from damage during delivery while also providing for a controlled release and delivery to the target site. This results in better pharmacokinetics, longer therapeutic lifetime, and improved patient adherence, and improve overall treatment outcomes for patients using polymeric carriers.

As pharmaceutical manufacturers continue to expand their pipelines to include biologic therapeutics, biosimilars, and nucleic acid-based medicines, the demand for new polymer formulations is increasing at a rapid rate. Advances in polymer chemistry have also allowed scientists to develop safer and more effective delivery systems capable of supporting the commercialization of cutting-edge therapies in the fields of oncology, immunology, rare diseases, and regenerative medicine.

To learn more about this report, download the PDF brochure

Polymer Type Segment Outlook

Owing to their high versatility, reproducibility and established usage, synthetic polymers currently hold the largest share of the polymer-based drug delivery systems market. Synthetic polymers allow for precise control over excellent control over drug release kinetics, biodegradability, mechanical strength, and scalability, making them suitable for nanoparticles, injectable depots, implants, and controlled-release formulations. Synthetic polymer-drug combinations also have widespread regulatory acceptance and compatibility with biologics and small-molecule drugs, which reinforces their position as the primary driver of the polymer-based drug delivery market.

Natural polymers are expected to register the highest growth over the forecast period, as demand for biodegradable, biocompatible and sustainable drug delivery materials continues to rise. The low toxicity and high bioactivity exhibited by natural polymers like chitosan, alginate, hyaluronic acid, gelatin, and cellulose derivatives among others make them attractive option for targeted drug delivery systems, tissue engineering and regenerative medicine. Growing interest in green biomaterials and advances in polymer modification processes are accelerating the development of delivery systems based on natural polymers.

Regional Outlook: Advanced healthcare infrastructure and strong pharmaceutical innovation drive North American market leadership

North America is expected to account for the largest share of the polymer-based drug delivery systems market due to its highly developed pharmaceutical and biotechnology industries, the presence of many leading pharmaceutical manufacturers, and significant investments in research and development. The region also has a high prevalence of chronic diseases and a strong adoption of innovative drug delivery technologies. Additional factors supporting market growth include favorable reimbursement policies for advanced therapeutics, robust regulatory support, and the continued commercialization of biologics and long-acting formulations.

Asia Pacific is expected to witness the highest growth over the forecast period. This growth is driven by expanding pharmaceutical manufacturing, rising healthcare expenditure, increasing biotechnology research, and the growing burden of chronic diseases. Countries such as China, India, Japan, and South Korea are making substantial investments in advanced drug delivery technologies and biologics development. Supportive government initiatives, improving healthcare infrastructure, and the expanding presence of contract development and manufacturing organizations (CDMOs) are further accelerating market growth across the region.

Competitive Landscape Analysis

The global polymer-based drug delivery systems market is marked by the presence of established and emerging market players such as

• Becton, Dickinson and Company (US)
• AbbVie Inc. (US)
• Johnson & Johnson (US)
• Medtronic (Ireland)
• Pfizer Inc. (US)
• Abbott (US)
• GSK plc. (UK)
• Bayer AG (Germany)
• Ashland (US)
• Corbion (The Netherlands)

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the polymer-based drug delivery systems market

Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In November 2025, Lupin launched Risperidone for Extended-Release Injectable Suspension in the US with 180-day CGT exclusivity following FDA approval, marking the first commercial product developed using its proprietary PrecisionSphere long-acting injectable platform. The launch validated PrecisionSphere's polymer-based microsphere technology for sustained drug release and strengthens Lupin's position in advanced long-acting injectable drug delivery while supporting future lifecycle management collaborations
• In November 2025, Halozyme Therapeutics acquired Elektrofi to expand its drug delivery portfolio with the proprietary Hypercon ultra-high concentration microparticle formulation technology for biologics, in a deal valued at up to USD 900 million. The acquisition strengthened Halozyme's polymer-based biologic delivery capabilities by enabling highly concentrated injectable formulations, supporting at-home administration, and expanding its long-term royalty-driven drug delivery business
• In November 2025, Curapath entered a co-exclusive licensing agreement with Cristal Therapeutics to integrate the CliCr bioconjugation platform into its polymer and lipid-based drug delivery portfolio. The partnership enables Curapath to exclusively offer the technology as a CDMO for targeted nucleic acid delivery using polymer and lipid nanoparticles, advancing next-generation targeted drug delivery solutions

Report Scope

Global Polymer-based Drug Delivery Systems Market Segmentation

This report by Medi-Tech Insights provides the size of the global polymer-based drug delivery systems market at the regional and country-level from 2024 to 2031. The report further segments the market by route of administration, polymer type, drug type, application, and end user.

Market Size & Forecast (2024-2031), By Route of Administration, USD Billion

• Oral
• Injectable
• Transdermal
• Topical
• Ophthalmic
• Nasal
• Pulmonary
• Other Routes of Administration

Market Size & Forecast (2024-2031), By Polymer Type, USD Billion

• Natural Polymers
  • Chitosan
  • Alginate
  • Gelatine
  • Hyaluronic Acid
  • Other Natural Polymers
• Synthetic Polymers
  • Poly Lactic-Co-Glycolic Acid (PLGA)
  • Poly Lactic Acid (PLA)
  • Polyethylene Glycol (PEG)
  • Polyvinyl Alcohol (PVA)
  • Other Synthetic Polymers
• Other Polymer Types

Market Size & Forecast (2024-2031), By Drug Type, USD Billion

• Small Molecules
• Biologics
• Vaccines
• Other Drug Types

Market Size & Forecast (2024-2031), By Application, USD Billion

• Oncology
• Cardiovascular Diseases
• Diabetes
• Infectious Diseases
• Neurological Disorders
• Autoimmune Diseases

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related reports for reference-

Global Injectable Drug Delivery Market Report Segmented by Device Type (Conventional & Self-Injectables, Needle-free Injectors), Route of Administration (Intravenous, Subcutaneous, Intramuscular), Therapeutic Application, Formulation Packaging, Forecast to 2031

 Global Oral Drug Delivery Technology Market Size & Trends Report Segmented by Dosage Form (Solid, Tablets, Capsules, Liquid, Gels), Delivery (Conventional, Controlled-release), Application (Oncology, CVDs, GI, CNS), End-user (Hospitals/Clinics, ASCs), & Regional Forecast to 2031

Global Nanoparticle Drug Delivery Systems Market Size & Trends Report Segmented by Type (LNP, Polymeric, Inorganic), Modality (Small Molecule, Biologics, CGT), Application (Oncology, CVDs), End-user Analysis, & Regional Forecast to 2031